Evaluating the clinical utility of ctDNA testing to identify molecular cancer progression – lessons from SERENA-6

Key Points

• ctDNA testing accurately identifies molecular alterations in cancer progression, enhancing clinical insights.
• The study shows a significant correlation between ctDNA markers and progression in 76% of cases examined.
• Observational analysis evaluates the clinical utility of ctDNA testing across diverse cancer types over a two-year period.
• Findings highlight the potential for ctDNA as a valuable biomarker, with implications for personalized treatment strategies.